Abstract OBJECTIVES: Tumor angiogenesis is an essential and complex process necessary for the growth of all tumors which represents a potential therapeutic target. Angiogenesis inhibitors targeting vascular endothelial growth factor (VEGF) or their receptor tyrosine kinases have been approved by the FDA. In thymic epithelial tumors (TET), targeted therapies have been sporadically applied due to their rarity. To ascertain the presence of potential therapeutic targets, we analyzed by immunohistochemistry the expression of angiogenesis-related biomarkers in a large series of TET arranged in Tissue Micro Arrays (TMA). MATERIALS AND METHODS: We assessed by immunohistochemistry the expression of the possible molecular target of anti-angiogenic therapy, i.e. VEGFA, VEGFC, VEGFD, VEGFR1, VEGFR2, VEGFR3, and PDGFRβ, in a TMA series of 200 TET collected in the framework of a multi-institutional collaborative project for Rare Diseases. RESULTS: When compared to the low-risk tumors, high-risk T

Objectives: Tumor angiogenesis is an essential and complex process necessary for the growth of all tumors which represents a potential therapeutic target. Angiogenesis inhibitors targeting vascular endothelial growth factor (VEGF) or their receptor tyrosine kinases have been approved by the FDA. In thymic epithelial tumors (TET), targeted therapies have been sporadically applied due to their rarity. To ascertain the presence of potential therapeutic targets, we analyzed by immunohistochemistry the expression of angiogenesis-related biomarkers in a large series of TET arranged in Tissue Micro Arrays (TMA). Materials and methods: We assessed by immunohistochemistry the expression of the possible molecular target of anti-angiogenic therapy, i.e. VEGFA, VEGFC, VEGFD, VEGFR1, VEGFR2, VEGFR3, and PDGFRβ, in a TMA series of 200 TET collected in the framework of a multi-institutional collaborative project for Rare Diseases. Results: When compared to the low-risk tumors, high-risk TET (B2, B3, carcinomas) contained higher proportion of cancer cells expressing VEGFA, VEGFC and VEGFD (P< 0.001, P< 0.001, and P< 0.001) growth factors, and their receptors VEGFR1 (P= 0.002), VEGFR2 (P= 0.013), and VEGFR3 (P= 0.041). No differences were observed in terms of PDGFRβ expression. Conclusions: According to our data, it is possible to hypothesize the existence of multiple paracrine and/or autocrine loops in TET, particularly in the high-risk ones, involved in TET growth and progression. Anti-angiogenic agents, directed to inhibit these loops, are therefore to be considered as potential tools in advanced TET therapy. © 2014 Elsevier Ireland Ltd.

Thymic epithelial tumors express vascular endothelial growth factors and their receptors as potential targets of antiangiogenic therapy: A tissue micro array-based multicenter study / Rossano, Lattanzio; Rossana La, Sorda; Francesco, Facciolo; Stefano, Sioletic; Libero, Lauriola; Robert, Martucci; Enzo, Gallo; Giovannella, Palmieri; Amelia, Evoli; Gabriele, Alessandrini; Ruco, Luigi; Rendina, Erino Angelo; Mauro, Truini; Roberto, Chiarle; Antonella, Barreca; Achille, Pich; Stefano, Ascani; Daniele, Remotti; Gianni, Tunesi; Pierluigi, Granone; Giovanni Battista, Ratto; Francesco, Puma; Pescarmona, Edoardo; Mauro, Piantelli; M., Thymic Epithelial Tumor Working Group Marino; Sandro, Carlini; Virna, Cerasoli; Felicita, Corzani; Enrico, Melis; Massimo, Filippetti; Paola, Canalini; Giorgio, Palestro; Maurizio, Lalle; Enrico, Ruffini; Anna, Ceribelli; Massimo, Rinaldi. - In: LUNG CANCER. - ISSN 0169-5002. - STAMPA. - 85:2(2014), pp. 191-196. [10.1016/j.lungcan.2014.05.010]

Thymic epithelial tumors express vascular endothelial growth factors and their receptors as potential targets of antiangiogenic therapy: A tissue micro array-based multicenter study

RUCO, Luigi;RENDINA, Erino Angelo;PESCARMONA, Edoardo;
2014

Abstract

Abstract OBJECTIVES: Tumor angiogenesis is an essential and complex process necessary for the growth of all tumors which represents a potential therapeutic target. Angiogenesis inhibitors targeting vascular endothelial growth factor (VEGF) or their receptor tyrosine kinases have been approved by the FDA. In thymic epithelial tumors (TET), targeted therapies have been sporadically applied due to their rarity. To ascertain the presence of potential therapeutic targets, we analyzed by immunohistochemistry the expression of angiogenesis-related biomarkers in a large series of TET arranged in Tissue Micro Arrays (TMA). MATERIALS AND METHODS: We assessed by immunohistochemistry the expression of the possible molecular target of anti-angiogenic therapy, i.e. VEGFA, VEGFC, VEGFD, VEGFR1, VEGFR2, VEGFR3, and PDGFRβ, in a TMA series of 200 TET collected in the framework of a multi-institutional collaborative project for Rare Diseases. RESULTS: When compared to the low-risk tumors, high-risk T
2014
Objectives: Tumor angiogenesis is an essential and complex process necessary for the growth of all tumors which represents a potential therapeutic target. Angiogenesis inhibitors targeting vascular endothelial growth factor (VEGF) or their receptor tyrosine kinases have been approved by the FDA. In thymic epithelial tumors (TET), targeted therapies have been sporadically applied due to their rarity. To ascertain the presence of potential therapeutic targets, we analyzed by immunohistochemistry the expression of angiogenesis-related biomarkers in a large series of TET arranged in Tissue Micro Arrays (TMA). Materials and methods: We assessed by immunohistochemistry the expression of the possible molecular target of anti-angiogenic therapy, i.e. VEGFA, VEGFC, VEGFD, VEGFR1, VEGFR2, VEGFR3, and PDGFRβ, in a TMA series of 200 TET collected in the framework of a multi-institutional collaborative project for Rare Diseases. Results: When compared to the low-risk tumors, high-risk TET (B2, B3, carcinomas) contained higher proportion of cancer cells expressing VEGFA, VEGFC and VEGFD (P< 0.001, P< 0.001, and P< 0.001) growth factors, and their receptors VEGFR1 (P= 0.002), VEGFR2 (P= 0.013), and VEGFR3 (P= 0.041). No differences were observed in terms of PDGFRβ expression. Conclusions: According to our data, it is possible to hypothesize the existence of multiple paracrine and/or autocrine loops in TET, particularly in the high-risk ones, involved in TET growth and progression. Anti-angiogenic agents, directed to inhibit these loops, are therefore to be considered as potential tools in advanced TET therapy. © 2014 Elsevier Ireland Ltd.
tissue micro array; thymic epithelial tumors; vascular endothelial growth factor; biomarkers; thymoma; vascular endothelial growth factor receptor
01 Pubblicazione su rivista::01a Articolo in rivista
Thymic epithelial tumors express vascular endothelial growth factors and their receptors as potential targets of antiangiogenic therapy: A tissue micro array-based multicenter study / Rossano, Lattanzio; Rossana La, Sorda; Francesco, Facciolo; Stefano, Sioletic; Libero, Lauriola; Robert, Martucci; Enzo, Gallo; Giovannella, Palmieri; Amelia, Evoli; Gabriele, Alessandrini; Ruco, Luigi; Rendina, Erino Angelo; Mauro, Truini; Roberto, Chiarle; Antonella, Barreca; Achille, Pich; Stefano, Ascani; Daniele, Remotti; Gianni, Tunesi; Pierluigi, Granone; Giovanni Battista, Ratto; Francesco, Puma; Pescarmona, Edoardo; Mauro, Piantelli; M., Thymic Epithelial Tumor Working Group Marino; Sandro, Carlini; Virna, Cerasoli; Felicita, Corzani; Enrico, Melis; Massimo, Filippetti; Paola, Canalini; Giorgio, Palestro; Maurizio, Lalle; Enrico, Ruffini; Anna, Ceribelli; Massimo, Rinaldi. - In: LUNG CANCER. - ISSN 0169-5002. - STAMPA. - 85:2(2014), pp. 191-196. [10.1016/j.lungcan.2014.05.010]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/583595
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 16
  • Scopus 32
  • ???jsp.display-item.citation.isi??? 30
social impact